Leap Therapeutics
Leap Therapeutics, based in Cambridge, MA, is dedicated to developing targeted and immuno-oncology therapeutics, with a focus on innovative treatments for various cancer types, including gastric, colorectal, and gynecologic cancers. Their lead candidate, DKN-01, is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is currently in clinical development for patients with DKK1-expressing tumors.
In addition to DKN-01, Leap Therapeutics is advancing FL-301, which targets Claudin18.2 for gastric and pancreatic cancers, and FL-501, a preclinical candidate that targets the growth and differentiation factor 15 (GDF-15) protein. The company is committed to understanding tumor expression and discovering new therapeutic targets and combinations to improve cancer treatment outcomes.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.



